What to know
Summary
Viruses
Illness
All data are preliminary and may change as more reports are received.
Directional arrows indicate changes between the current week and the previous week. Additional information on the arrows can be found at the bottom of this page.
A description of the ÐÇ¿ÕÓéÀÖ¹ÙÍø influenza surveillance system, including methodology and detailed descriptions of each data component is available on the surveillance methods page.1
Additional information on the current and previous influenza seasons for each surveillance component are available on FluView Interactive.
U.S. virologic surveillance
Nationally, the percentage of respiratory specimens testing positive for influenza virus in clinical laboratories remained stable (change ≤ 0.5 percentage points) compared to the previous week but is higher than it has been all season. Percent positivity is increasing in HHS regions 1, 2, 3, 5, 7, and 10, and decreasing in HHS regions 4, 6, 8, and 9. Region 5 had the highest percent positivity (35.9%), and Region 4 had the lowest (25.9%). Influenza A(H1N1)pdm09 and A(H3N2) were the predominant viruses reported this week. For regional and state level data and age group distribution, please visit FluView Interactive. Viruses known to be associated with recent receipt of live attenuated influenza vaccine (LAIV) or found upon further testing to be a vaccine virus are not included, as they are not circulating influenza viruses.
Clinical Laboratories
The results of tests performed by clinical laboratories nationwide are summarized below. Data from clinical laboratories (the percentage of specimens tested that are positive for influenza virus) are used to monitor whether influenza activity is increasing or decreasing.
| Week 6 | Data Cumulative since September 29, 2024 (Week 40) |
|
|---|---|---|
| No. of specimens tested | 150,006 | 2,010,657 |
| No. of positive specimens (%) | 47,328 (31.6%) | 289,283 (14.4%) |
| Positive specimens by type | ||
| Influenza A | 44,757 (94.6%) | 278,541 (96.3%) |
| Influenza B | 2,571 (5.4%) | 10,741 (3.7%) |
Public Health Laboratories
The results of tests performed by public health laboratories nationwide are summarized below. Data from public health laboratories are used to monitor the proportion of circulating influenza viruses that belong to each influenza subtype/lineage.
| Week 6 |
Data Cumulative since September 29, 2024 (Week 40) |
|
|---|---|---|
| No. of specimens tested | 5,469 | 73,784 |
| No. of positive specimens | 4,214 | 46,817 |
| Positive specimens by type/subtype | ||
| Influenza A | 4,079 (96.8%) | 45,582 (97.4%) |
| Subtyping Performed | 3,146 (77.1%) | 40,278 (88.4%) |
| (H1N1)pdm09 | 1,742 (55.4%) | 19,511 (48.4%) |
| H3N2 | 1,404 (44.6%) | 20,688 (51.4%) |
| H3N2v | 0 | 0 |
| H5* | 0 | 79 (0.2%) |
| Subtyping not performed | 933 (22.9%) | 5,304 (11.6%) |
| Influenza B | 135 (3.2%) | 1,235 (2.6%) |
| Lineage testing performed | 22 (16.3%) | 572 (46.3%) |
| Yamagata lineage | 0 | 0 |
| Victoria lineage | 22 (100%) | 572 (100%) |
| Lineage not performed | 113 (83.7%) | 663 (53.7%) |
*This data reflects specimens tested and the number determined to be positive for influenza viruses at the public health labs (specimens tested is not the same as cases). It does not reflect specimens tested only at ÐÇ¿ÕÓéÀÖ¹ÙÍø and could include more than one specimen tested per person. The guidance for influenza A/H5 testing recommends testing both a conjunctival and respiratory swab for people with conjunctivitis which has resulted in more specimens testing positive for influenza A/H5 than the number of human H5 cases. For more information on the number of people infected with A/H5, please visit the "How ÐÇ¿ÕÓéÀÖ¹ÙÍø is monitoring influenza data among people to better understand the current avian influenza A (H5N1) situation"
Novel Influenza A Virus
One confirmed human infection with avian influenza A(H5) virus was reported to ÐÇ¿ÕÓéÀÖ¹ÙÍø this week. To date, human-to-human transmission of avian influenza A(H5) virus has not been identified in the United States.
The case was reported by the Nevada Department of Public Health and occurred in a worker aged ≥18 years at a commercial dairy cattle farm in an area where highly pathogenic avian influenza (HPAI) A(H5N1) viruses had been detected in cows. This individual developed conjunctivitis, which they reported to the local health department. Specimens were collected from the individual and initially tested at the state public health laboratory using the ÐÇ¿ÕÓéÀÖ¹ÙÍø influenza A(H5) assay before being sent to ÐÇ¿ÕÓéÀÖ¹ÙÍø for further testing. Avian influenza A(H5N1) virus was confirmed at ÐÇ¿ÕÓéÀÖ¹ÙÍø. This is the first human influenza A(H5) case in Nevada.
Notification to WHO of this case was completed per International Health Regulations (IHR). More information regarding IHR can be found at .
The CSTE position statement, which includes updated case definitions for confirmed, probable, and suspected cases is available at
An up-to-date human case summary during the 2024 outbreak by state and exposure source is available at www.cdc.gov/bird-flu/situation-summary/index.html
Information about avian influenza is available at /flu/avianflu/index.htm.
Interim recommendations for Prevention, Monitoring, and Public Health Investigations are available at /bird-flu/prevention/hpai-interim-recommendations.html.
The latest case reports on avian influenza outbreaks in wild birds, commercial poultry, backyard or hobbyist flocks, and mammals in the United States are available from the USDA at .
Influenza Virus Characterization
ÐÇ¿ÕÓéÀÖ¹ÙÍø performs genetic and antigenic characterization of U.S. viruses submitted from state and local public health laboratories according to the Right Size Roadmap submission . These data are used to compare how similar the currently circulating influenza viruses are relative to the reference viruses representing the current influenza vaccines. The data are also used to monitor evolutionary changes that continually occur in influenza viruses circulating in humans. ÐÇ¿ÕÓéÀÖ¹ÙÍø also tests susceptibility of circulating influenza viruses to antiviral medications including the neuraminidase inhibitors (oseltamivir, zanamivir, and peramivir) and the polymerase acidic protein (PA) endonuclease inhibitor baloxavir. The HA clade and subclades were assigned using Nextclade ().
ÐÇ¿ÕÓéÀÖ¹ÙÍø has genetically characterized 1,687 influenza viruses collected since September 29, 2024.
| Virus Subtype or Lineage | Genetic Characterization | ||||
|---|---|---|---|---|---|
| Total No. of Subtype/Lineage Tested |
HA Clade |
Number (% of subtype/lineage tested) |
HA Subclade |
Number (% of subtype/lineage tested) |
|
| A/H1 | 632 | ||||
| 5a.2a | 374 (59.2%) | C.1.9 | 374 (59.2%) | ||
| 5a.2a.1 | 258 (40.8%) | D | 19 (3.0%) | ||
| D.1 | 4 (0.6%) | ||||
| D.3 | 82 (13.0%) | ||||
| D.5 | 153 (24.2%) | ||||
| A/H3 | 928 | ||||
| 2a.3a | 5 (0.5%) | G.1.3.1 | 5 (0.5%) | ||
| 2a.3a.1 | 923 (99.5%) | J.1 | 1 (0.1%) | ||
| J.1.1 | 6 (0.6%) | ||||
| J.2 | 847 (91.3%) | ||||
| J.2.1 | 21 (2.3%) | ||||
| J.2.2 | 48 (5.2%) | ||||
| B/Victoria | 127 | ||||
| 3a.2 | 127 (100%) | C.3 | 2 (1.6%) | ||
| C.5 | 15 (11.8%) | ||||
| C.5.1 | 70 (55.1%) | ||||
| C.5.6 | 14 (11.0%) | ||||
| C.5.7 | 26 (20.5%) | ||||
| B/Yamagata | 0 | ||||
| Y3 | 0 | Y3 | 0 | ||
ÐÇ¿ÕÓéÀÖ¹ÙÍø antigenically characterizes influenza viruses by hemagglutination inhibition (HI) (H1N1pdm09, H3N2, B/Victoria, and B/Yamagata viruses) or neutralization-based (H3N2 viruses) using antisera that ferrets make after being infected with reference viruses representing the 2023-2024 Northern Hemisphere recommended cell or recombinant-based vaccine viruses. Antigenic differences between viruses are determined by comparing how well the antibodies made against the vaccine reference viruses recognize the circulating viruses that have been grown in cell culture. Ferret antisera are useful because antibodies raised against a particular virus can often recognize small changes in the surface proteins of other viruses. In HI assays, viruses with similar antigenic properties have antibody titer differences of less than or equal to 4-fold when compared to the reference (vaccine) virus. In HINT, viruses with similar antigenic properties have antibody neutralization titer differences of less than or equal to 8-fold. Viruses selected for antigenic characterization are a subset representing the genetic changes in the surface proteins seen in genetically characterized viruses.
Influenza A Viruses
- A (H1N1)pdm09: 103 A(H1N1)pdm09 viruses were antigenically characterized by HI, and 103 (100%) were well-recognized (reacting at titers that were within 4-fold of the homologous virus titer) by ferret antisera to cell-grown A/Wisconsin/67/2022-like reference viruses representing the A(H1N1)pdm09 component for the cell- and recombinant-based influenza vaccines.
- A(H3N2): 169 A(H3N2) viruses were antigenically characterized by HI or HINT, and 86 (50.9%) were well-recognized (reacting at titers that were within 4-fold of the homologous virus titer in HI or reacting at titers that were less than or equal to 8-fold of the homologous virus in HINT) by ferret antisera to cell-grown A/Massachusetts/18/2022-like reference viruses representing the A(H3N2) component for the cell- and recombinant-based influenza vaccines.
Influenza B Viruses
- B/Victoria: 51 influenza B/Victoria-lineage virus were antigenically characterized by HI, and all were well-recognized (reacting at titers that were within 4-fold of the homologous virus titer) by ferret antisera to cell-grown B/Austria/1359417/2021-like reference viruses representing the B/Victoria component for the cell- and recombinant-based influenza vaccines.
- B/Yamagata: No influenza B/Yamagata-lineage viruses were available for antigenic characterization.
Assessment of Virus Susceptibility to Antiviral Medications
ÐÇ¿ÕÓéÀÖ¹ÙÍø assesses susceptibility of influenza viruses to the antiviral medications including the neuraminidase inhibitors (oseltamivir, zanamivir, and peramivir) and the PA endonuclease inhibitor baloxavir using next generation sequence analysis supplemented by laboratory assays. Information about antiviral susceptibility test methods can be found at U.S. Influenza Surveillance: Purpose and Methods.
Viruses collected in the U.S. since September 29, 2024, were tested for antiviral susceptibility as follows:
| Antiviral Medication | Total Viruses | A/H1 | A/H3 | B/Victoria | ||
|---|---|---|---|---|---|---|
| Neuraminidase Inhibitors | Oseltamivir | Viruses Tested | 1,627 | 612 | 892 | 123 |
| Reduced Inhibition | 1 (<0.1%) | 1 (0.2%) | 0 | 0 | ||
| Highly Reduced Inhibition | 3 (0.2%) | 3 (0.5%) | 0 | 0 | ||
| Peramivir | Viruses Tested | 1,627 | 612 | 892 | 123 | |
| Reduced Inhibition | 0 | 0 | 0 | 0 | ||
| Highly Reduced Inhibition | 3 (0.2%) | 3 (0.5%) | 0 | 0 | ||
| Zanamivir | Viruses Tested | 1,627 | 612 | 892 | 123 | |
| Reduced Inhibition | 1 (0.02%) | 0 | 0 | 0 | ||
| Highly Reduced Inhibition | 0 (0%) | 0 | 0 | 0 | ||
| PA Cap-Dependent Endonuclease Inhibitor | Baloxavir | Viruses Tested | 1,541 | 538 | 886 | 117 |
| Decreased Susceptibility | 0 | 0 | 0 | 0 | ||
Three A(H1N1)pdm09 viruses had NA-H275Y amino acid substitution conferring highly reduced inhibition by oseltamivir and peramivir. One A(H1N1)pdm09 virus had NA-I223V and NA-S247N amino acid substitutions and showed reduced inhibition by oseltamivir.
High levels of resistance to the adamantanes (amantadine and rimantadine) persist among influenza A(H1N1)pdm09 and influenza A(H3N2) viruses (the adamantanes are not effective against influenza B viruses). Therefore, use of these antivirals for treatment and prevention of influenza A virus infection is not recommended and data from adamantane resistance testing are not presented.
Outpatient and Emergency Department Illness Surveillance
Outpatient respiratory illness visits
The U.S. Outpatient Influenza-like Illness Surveillance Network (ILINet) monitors outpatient visits for respiratory illness referred to as influenza-like illness [ILI (fever plus cough or sore throat)], not laboratory-confirmed influenza, and will therefore capture respiratory illness visits due to infection with any pathogen that can present with similar symptoms, including influenza virus, SARS-CoV-2, and RSV. It is important to evaluate syndromic surveillance data, including that from ILINet, in the context of other sources of surveillance data to obtain a complete and accurate picture of influenza, SARS-CoV-2, and other respiratory virus activity.
Nationally, during Week 6, 7.8% of patient visits reported through ILINet were due to respiratory illness that included fever plus a cough or sore throat, also referred to as ILI. This week's percentage remained stable (change of ≤ 0.1 percentage points) compared to Week 5 but is higher than it has been all season and remains above the national baseline of 3.0% for the eleventh consecutive week. The percentage of visits for ILI increased (change of > 0.1 percentage points) in HHS regions 1, 3, 5, 7, 8, and 10, decreased in HHS regions 2, 4, and 6, and remained stable in Region 9 this week compared to last. All regions remain above their respective baselines. Multiple respiratory viruses are co-circulating, and the relative contribution of influenza virus infections to ILI varies by location.
Outpatient respiratory illness visits by age group
About 70% of ILINet participants provide both the number of patient visits for respiratory illness and the total number of patient visits for the week broken out by age group. Based on these data, the percentage of visits for respiratory illness increased (change of > 0.1 percentage point) in the 0-4 years, 5-24 years, and 65+ years and remained stable (change of ≤ 0.1 percentage point) in the 25-49 years and 50-64 years in Week 6 compared to Week 5.
Outpatient respiratory illness activity map
Data collected in ILINet are used to produce a measure of by state/jurisdiction and Core Based Statistical Areas (CBSA). The state of Vermont is working with ÐÇ¿ÕÓéÀÖ¹ÙÍø to ensure that appropriate data are being used to calculate the state's activity level. Vermont's activity level will be reported again after the issue is resolved.
| Activity Level | Number of Jurisdictions | Number of CBSAs | ||
|---|---|---|---|---|
| Week 6 (Week ending Feb. 8, 2025) |
Week 5 (Week ending Feb. 1, 2025) |
Week 6 (Week ending Feb. 8, 2025) |
Week 5 (Week ending Feb. 1, 2025) |
|
| Very High | 37 | 34 | 125 | 123 |
| High | 9 | 11 | 254 | 228 |
| Moderate | 2 | 3 | 113 | 130 |
| Low | 3 | 1 | 117 | 114 |
| Minimal | 3 | 5 | 93 | 111 |
| Insufficient Data | 1 | 1 | 227 | 223 |
*Data collected in ILINet may disproportionally represent certain populations within a jurisdiction or CBSA, and therefore, may not accurately depict the full picture of influenza activity for the entire jurisdiction or CBSA. Differences in the data presented here by ÐÇ¿ÕÓéÀÖ¹ÙÍø and independently by some health departments likely represent differing levels of data completeness with data presented by the health department likely being the more complete.
National Syndromic Surveillance System (NSSP)
The overall percentage of emergency department (ED) visits with a discharge diagnosis of influenza reported in NSSP was 7.9% during Week 6, a slight decrease (change of > 0.1 percentage point) compared to the previous week. The percentage of ED visits with influenza discharge diagnoses decreased in HHS regions 2, 4, 6, and 9, and increased (change of > 0.1 percentage point) in HHS regions 1, 3, 5, 7, 8, and 10. The percentage also decreased in the 5-17 and 18-64 years age groups and remained stable (change of ≤ 0.1 percentage point) in the 0-4 and 65+ years age groups.
Hospitalization surveillance
FluSurv-Net
The Influenza Hospitalization Surveillance Network (FluSurv-NET) conducts population-based surveillance for laboratory-confirmed influenza-related hospitalizations in select counties in 14 states and represents approximately 9% of the U.S. population. FluSurv-NET hospitalization data are preliminary. As data are received each week, prior case counts and rates are updated accordingly.
A total of 23,917 laboratory-confirmed influenza-associated hospitalizations were reported by FluSurv-NET sites between October 1, 2024, and February 8, 2025. The weekly hospitalization rate observed during Week 6 was 9.6 per 100,000 population. The weekly hospitalization rate observed during Week 5 (12.8 per 100,000 population) is the highest peak weekly rate observed across all seasons since 2010-2011. The cumulative hospitalization rate observed in Week 6 was 78.1 per 100,000 population, which is the highest cumulative hospitalization rate for Week 6 across all seasons since 2010-11.
Among all hospitalizations, 23,399 (97.8%) were associated with influenza A virus, 387 (1.6%) with influenza B virus, 20 (0.1%) with influenza A virus and influenza B virus co-infection, and 111 (0.5%) with influenza virus for which the type was not determined. Among those with influenza A subtype information, 2,921 (53.5%) were A(H1N1) pdm09 and 2,539 (46.5%) were A(H3N2).
When examining rates by age, the highest cumulative hospitalization rate per 100,000 population was among adults aged 65 years and older (241.1), followed by adults aged 50-64 years (92.0), children aged 0-4 years (66.4), adults aged 18-49 (33.2), and children aged 5-17 (23.4).
When examining age-adjusted rates by race and ethnicity, the highest cumulative hospitalization rate per 100,000 population was among non-Hispanic Black persons (115.1), followed by American Indian/Alaska Native persons (102.9), Hispanic persons (63.4), non-Hispanic White persons (59.5), and Asian/Pacific Islander persons (47.8).
Among 2,192 hospitalized adults with information on underlying medical conditions, 95.1% had at least one reported underlying medical condition; the most commonly reported were hypertension, cardiovascular disease, metabolic disease, and obesity. Among 1,161 hospitalized women of childbearing age (15-49 years) with information on pregnancy status, 28.9% were pregnant. Among 379 hospitalized children with information on underlying medical conditions, 53.1% had at least one reported underlying medical condition; the most commonly reported was asthma, followed by neurologic disease and obesity.
National Healthcare Safety Network (NHSN) Hospital Respiratory Data
Hospitals report to NHSN the weekly number of patients with laboratory-confirmed influenza who were admitted to the hospital. Nationally, during Week 6, 50,382 laboratory confirmed influenza-associated hospitalizations were reported. This week's influenza-associated hospitalizations remained stable (change of < 5%) compared to Week 5 and is higher than it has been all season.
The weekly hospital admission rate observed in Week 6 was 14.9 per 100,000. The weekly rate of hospital admissions in all 10 HHS regions ranged from 8.8 (Region 10) to 19.5 (Region 3). The weekly rate of hospital admissions increased in HHS regions 1, 3, 5, 8, and 10, remained stable in HHS regions 2, 4, and 7, and decreased in HHS regions 6 and 9.
When examining rates by age for Week 6, the 0-4 age group increased, the 18-49 age group decreased, and all other age groups remained stable compared to the previous week. The highest hospital admission rate per 100,000 population was among those 75+ years (65.1), followed by 65-74 years (31.1), and 50-64 years (16.2).
Mortality surveillance
National Center for Health Statistics (NCHS)
Based on NCHS mortality surveillance data available on February 13, 2025, 2.6% of the deaths that occurred during the week ending February 8, 2025 (Week 6), were due to influenza. This percentage increased (> 0.1 percentage point change) compared to Week 5 and is higher than it has been all season. The data presented are preliminary and may change as more data are received and processed.
Influenza-Associated Pediatric Mortality
Eleven influenza-associated pediatric deaths occurring during the 2024-2025 season were reported to ÐÇ¿ÕÓéÀÖ¹ÙÍø during Week 6. The deaths occurred between Week 51 of 2024 (the week ending December 21, 2024) and Week 6 of 2025 (the week ending February 8, 2025). Ten deaths were associated with influenza A viruses. Six of the influenza A viruses had subtyping performed; three were A(H1N1) viruses and three were A(H3N2) viruses. One death was associated with an influenza B/Victoria virus.
A total of 68 influenza-associated pediatric deaths occurring during the 2024-2025 season have been reported to ÐÇ¿ÕÓéÀÖ¹ÙÍø.
Additional National and International Influenza Surveillance Information
Indicators Status by System
Increasing: 
Decreasing: 
Stable: 
Clinical Labs: Up or down arrows indicate a change of greater than or equal to 0.5 percentage points in the percent of specimens positive for influenza compared to the previous week.
Outpatient Respiratory Illness (ILINet): Up or down arrows indicate a change of greater than 0.1 percentage points in the percent of visits due to respiratory illness (ILI) compared to the previous week.
NHSN Hospitalizations: Up or down arrows indicate change of greater than or equal to 5% of the number of patients admitted with laboratory-confirmed influenza compared to the previous week.
NCHS Mortality: Up or down arrows indicate change of greater than 0.1 percentage points of the percent of deaths due to influenza compared to the previous week.
Additional surveillance information
FluView Interactive: FluView includes enhanced web-based interactive applications that can provide dynamic visuals of the influenza data collected and analyzed by ÐÇ¿ÕÓéÀÖ¹ÙÍø. These FluView Interactive applications allow people to create customized, visual interpretations of influenza data, as well as make comparisons across flu seasons, regions, age groups and a variety of other demographics.
National Institute for Occupational Safety and Health: Monthly surveillance data on the prevalence of health-related workplace absenteeism among full-time workers in the United States are available from NIOSH.
U.S. State and local influenza surveillance: Select a jurisdiction below to access the latest local influenza information.
Public Health Agency of Canada:
The most up-to-date influenza information from Canada is available in .
Public Health England:
The most up-to-date influenza information from the United Kingdom is available from .
Any links provided to non-Federal organizations are provided solely as a service to our users. These links do not constitute an endorsement of these organizations or their programs by ÐÇ¿ÕÓéÀÖ¹ÙÍø or the Federal Government, and none should be inferred. ÐÇ¿ÕÓéÀÖ¹ÙÍø is not responsible for the content of the individual organization web pages found at these links.
A description of the ÐÇ¿ÕÓéÀÖ¹ÙÍø influenza surveillance system, including methodology and detailed descriptions of each data component is available on the page.